Continuing Push to Diversify Offerings, Myriad Licenses Chronix's Early Cancer Detection Technology

Chronix has yet to complete validation studies for its prostate, breast, and colon early detection cancer tests, so questions remain as to when the license will begin adding to Myriad's revenues.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.